Bruce Thompson

Bruce Thompson, PhD is currently the Vice President and Technical Lead for the Cell Therapy Franchise at Resilience, Inc. He has over 15 years of CMC strategy, product development and cell therapy manufacturing experience. Most recently, he was Vice President of Process Sciences at Lyell Immunopharma, where he was responsible for Process and Analytical Development, as well as lentiviral vector sciences and tech transfer of processes and methods to a newly built state-of-the-art cGMP facility. Prior to Lyell, Bruce was the Sr. Director of the Fred Hutchinson Cancer Research Center (FHCRC) Therapeutic Products Program, where we led the GMP manufacturing of cell and gene therapy products. He was responsible for supporting >15 active clinical programs and contributed to the filing of 6 INDs for various cell therapy programs.

Before joining FHCRC, Bruce led a number of CMC development teams at Pfizer, Inc., gaining significant drug development experience in monoclonal antibodies and vaccine antigens and was heavily involved in building the CMC team at Pfizer that partnered with the French companies, Servier and Cellectis, on the development of the TALEN-mediated allogeneic CAR-T CD19 (UCART19) programs in the EU and US. Bruce also has significant expertise in the development of analytical control strategies, potency assays and heightened characterization activities for the development of biological, nucleic acid and cellular therapy products.

Bruce received his B.A. in Biology and Ph.D. in Microbiology and Immunology from the University of Louisville. He then completed a postdoctoral fellowship at Washington University in St. Louis.